Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists Source In both trials, after 72 weeks of treatment, patients who received Zepbound at all three dose levels experienced a statistically significant reduction in body weight compared to those who received placebo, and greater proportions of patients who received Zepbound achieved at least 5% weight reduction compared to placebo
It was also the reason Lilly fast-tracked the compound into a large, multi-trial Phase 3 program rather than running additional Phase 2 work
Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects
Testosterone propionate offers more frequent dosing requirements but provides tighter hormone control and less water retention
Lancet Diabetes & Endocrinology , 7 (11), 834844
What this adds up to clinically: GLP-1s are best understood as treating the underlying metabolic disease, not just as a weight loss intervention
